HESTER BIOSCIENCES LTD
HESTERBIO · NSE · Healthcare
With a 20% margin of safety, our buy-below price is ₹1,371.87.
Investability checklist
- ✓ROE above 15%16.6%
- ✕Low debt (D/E < 0.5)0.53x
- ✓Positive free cash flow
- ✓Revenue growth > 10%38%
- ✓Earnings growing969%
- ✓Net margin ≥ 10%16.7%
- ✕Current ratio > 1.51.37
- ✕Below our fair value
- ✕Margin of safety ≥ 20%
- ✓Above 200-day average
- ✓Above 50-day average
- –Positive 1-year return
- –Altman Z in safe zone
- –Piotroski ≥ 7
1-year price
EOD · 2026-06-16Our scores
Durability rewards strong, low-debt, profitable businesses; Valuation rewards stocks cheap vs their sector; Momentum rewards strong price trends.
Shareholding
Promoter holding via insider stake; institutional via reported holdings.
Key fundamentals
SWOT snapshot
Strengths
- •Healthy profit margin (16.7%).
Opportunities
- •Earnings growing (969% YoY).
- •Revenue growing (38% YoY).
- •Trading in our value buy zone versus sector peers.
About HESTER BIOSCIENCES LTD
Hester Biosciences Limited manufactures and trades in veterinary vaccines and animal health products in India and internationally. It operates through the Poultry Healthcare and Animal Healthcare segments. The company provides poultry vaccines for newcastle disease, infectious bronchitis, infectious bursal, fowl pox, marek's disease, infectious coryza, fowl cholera, inclusion body hepatitis, fowl typhoid, and avian encephalomyelitis
More in Healthcare
Our verdict, fair value, financial-health and checklist are StocksWizard's own estimates, computed from public end-of-day data using standard models (DCF, relative valuation, Altman Z, Piotroski). For information only — not investment advice or a recommendation. Verify independently before investing.